These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 38808486)
1. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Kohan DE; Bedard PW; Jenkinson C; Hendry B; Komers R Clin Sci (Lond); 2024 Jun; 138(11):645-662. PubMed ID: 38808486 [TBL] [Abstract][Full Text] [Related]
2. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R; J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325 [TBL] [Abstract][Full Text] [Related]
3. Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist. Chiu AW; Bredenkamp N Ann Pharmacother; 2024 Jun; 58(6):645-656. PubMed ID: 37706310 [TBL] [Abstract][Full Text] [Related]
4. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis. Komers R; Diva U; Inrig JK; Loewen A; Trachtman H; Rote WE Kidney Int Rep; 2020 Apr; 5(4):494-502. PubMed ID: 32274453 [TBL] [Abstract][Full Text] [Related]
5. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. Reily C; Moldoveanu Z; Pramparo T; Hall S; Huang ZQ; Rice T; Novak L; Komers R; Jenkinson CP; Novak J Am J Physiol Renal Physiol; 2024 May; 326(5):F862-F875. PubMed ID: 38511222 [TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. Cosgrove D; Gratton MA; Madison J; Vosik D; Samuelson G; Meehan D; Delimont D; Phillips G; Smyth B; Pramparo T; Jarocki D; Nguyen M; Komers R; Jenkinson C J Pathol; 2023 Jul; 260(3):353-364. PubMed ID: 37256677 [TBL] [Abstract][Full Text] [Related]
7. Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. Trachtman H; Komers R; Inrig J Expert Rev Clin Immunol; 2024 Jun; 20(6):571-576. PubMed ID: 38362830 [TBL] [Abstract][Full Text] [Related]
8. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nagasawa H; Ueda S; Suzuki H; Jenkinson C; Fukao Y; Nakayama M; Otsuka T; Okuma T; Clapper W; Liu K; Nguyen M; Komers R; Suzuki Y Nephrol Dial Transplant; 2024 Aug; 39(9):1494-1503. PubMed ID: 38271614 [TBL] [Abstract][Full Text] [Related]
9. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice. Campbell KN; Griffin S; Trachtman H; Geletka R; Wong MG Int J Nephrol Renovasc Dis; 2023; 16():281-291. PubMed ID: 38149041 [TBL] [Abstract][Full Text] [Related]
10. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety. Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). Komers R; Gipson DS; Nelson P; Adler S; Srivastava T; Derebail VK; Meyers KE; Pergola P; MacNally ME; Hunt JL; Shih A; Trachtman H Kidney Int Rep; 2017 Jul; 2(4):654-664. PubMed ID: 29142983 [TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system blockade alone or combined with ET Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis. Wada R; Kleijn HJ; Zhang L; Chen SC CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1080-1092. PubMed ID: 37221817 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V; Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634 [TBL] [Abstract][Full Text] [Related]
16. The Evidence for Sparsentan-Mediated Inhibition of Chuang TH; Cho HY; Wu SN Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052766 [TBL] [Abstract][Full Text] [Related]
17. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Barratt J; Rovin B; Wong MG; Alpers CE; Bieler S; He P; Inrig J; Komers R; Heerspink HJL; Mercer A; Noronha IL; Radhakrishnan J; Rheault MN; Rote W; Trachtman H; Trimarchi H; Perkovic V; Kidney Int Rep; 2023 May; 8(5):1043-1056. PubMed ID: 37180506 [TBL] [Abstract][Full Text] [Related]